| Literature DB >> 24320748 |
Haipeng Sun, Yifan Yang, Ting Xue1, Baolin Sun.
Abstract
BACKGROUND: Vancomycin has been the medication of last resort to cure infections caused by Staphylococcus aureus since the increase in the prevalence of methicillin-resistant Staphylococcus aureus (MRSA). Some strains have developed vancomycin-intermediate resistance, which is generally associated with altered expression of or mutations in some part of the two-component system (TCS), such as GraSR, VraSR, and WalKR.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24320748 PMCID: PMC4029521 DOI: 10.1186/1471-2180-13-286
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Strains and plasmids used in this study
| Strains | | |
| NCTC8325 | Wild-type | NARSAa |
| RN4220 | 8325-4 r- initial recipient for modification of plasmids which are introduced into | NARSA |
| ΔairSR | 8325 | This study |
| CairSR | 8325 | This study |
| DH5α | Clone host strain, | TransGen |
| BL21 (DE3) | Express strain, F- | TransGen |
| Plasmids | | |
| pEasy-blunt simple | Clone vector, Kanr Apr b | TransGen |
| pET28a(+) | Expression vector with a hexahistidine tag, Kanr | Novagen |
| pEairR | pET28a(+) with the | This study |
| pEairS | pET28a(+) with the | This study |
| pEC1 | pUC18 derivative, source of the | Bruckner |
| pBT2 | Shuttle vector, temperature sensitive, Apr Cmr | Bruckner |
| pBTairSR | pBT2 containing upstream and downstream fragments of | This study |
| pLI50 | Shuttle cloning vector, Apr Cmr | Addgene |
| pLIairSR | pLI50 with | This study |
aNARSA, Network on Antimicrobial Resistance in Staphylococcus aureus;
bKanr, kanamycin-resistant; Apr, ampicillin-resistant; Cmr, chloramphenicol-resistant; Emr, erythromycin-resistant.
Primers used in this study
| up-airSR-f | CCGgaattcTACATCTTGTGCCTTAG | |
| up-airSR-r | ATTTGAGatcgatAATGTTCAG | |
| down-airSR-f | CGATTTAAGTggtaccGTTGCATGATGTG | |
| down-airSR-r | CGCggatccCCTTAAGTTGTTGGAA | |
| Em-f | CGGatcgatGATACAAATTCCCCGTAGGC | |
| Em-r | CGGggtaccGAAATAGATTTAAAAATTTCGC | |
| c-airSR-f | CGCggatccATCGTCGCCAGTATG | ΔairS complementation |
| c-airSR-r | CCGgaattcTGAAGCGAAAGTAAATG | ΔairS complementation |
| e-airR-f | GGAATTCcatatgAACAAAGTAATATT | expression of AirR |
| e-airR-r | CCGctcgagAATCAACTTATTTTCCA | expression of AirR |
| e-airS-f | GGGAATTCcatatgATGGAACAAAGGACGCGACTAG | expression of AirS |
| e-airS-r | CCGctcgagCTATTTTATAGGAATTGTGAATTG | expression of AirS |
| RTQ-cap5B-f | GCTTATTGGTTACTTCTGA | real-time RT PCR |
| RTQ-cap5B-r | GTTGGCTTACGCATATC | real-time RT PCR |
| RTQ-cap5D-f | ATATGCCAGTGTGAGTGA | real-time RT PCR |
| RTQ-cap5D-r | CGGTCTATTGCCTGTAAC | real-time RT PCR |
| RTQ-lytM-f | CATTCGTAGATGCTCAAGGA | real-time RT PCR |
| RTQ-lytM-r | CTCGCTGTGTAGTCATTGT | real-time RT PCR |
| RTQ-640-f | TGATGGGACAGGAGT | real-time RT PCR |
| RTQ-640-r | TATTGTGCCGCTTCT | real-time RT PCR |
| RTQ-953-f | GTCATTGAGCACGATTTATT | real-time RT PCR |
| RTQ-953-r | TCTGGGCGGCTGTAA | real-time RT PCR |
| RTQ-pbp1-f | AGTCAGCGACCAACATT | real-time RT PCR |
| RTQ-pbp1-r | AAGCACCTTCTTGAATAGC | real-time RT PCR |
| RTQ-murD-f | TTCAGGAATAGAGCATAGA | real-time RT PCR |
| RTQ-murD-r | AACCACCACATAACCAA | real-time RT PCR |
| RTQ-1148-f | GCCGAAGTGACATAC | real-time RT PCR |
| RTQ-1148-r | AAGCACCGACTGATA | real-time RT PCR |
| RTQ-ddl-f | TAGGGTCAAGTGTAGGT | real-time RT PCR |
| RTQ-ddl-r | GTCGCTTCAGGATAG | real-time RT PCR |
| RTQ-pta-f | AAAGCGCCAGGTGCTAAATTAC | real-time RT PCR |
| RTQ-pta-r | CTGGACCAACTGCATCATATCC | real-time RT PCR |
| p-cap5A-f | TCATCTAACTCACCTGAAATTACAAAA | EMSA |
| p-cap5A-r | TTTCCATTATTTACCTCCCTTAAAAA | EMSA |
| p-ddl-f | CAAACTCCTTTTATACTC | EMSA |
| p-ddl-r | GTCATTTCGTTTTCCT | EMSA |
| p-pbp1-f | GATTCAATAGAACAAGCGATT | EMSA |
| p-pbp1-r | AGCTACACGTAATTTCGCGCTT | EMSA |
| p-lytM-f | GAATCGCGAACATGGACGAA | EMSA |
| p-lytM-r | GCAATCGCTGCTGCTGTTAA | EMSA |
aThe sequences in lowercase letters refer to the restriction endonuclease recognition sites.
Cell wall synthesis-related genes that were differentially expressed in the mutant compared to the NCTC8325 wild-type
| SAOUHSC_00114 | Capsular polysaccharide biosynthesis protein, putative | −3.61 | |
| SAOUHSC_00115 | Capsular polysaccharide synthesis enzyme Cap5B | −2.86 | |
| SAOUHSC_00116 | Capsular polysaccharide synthesis enzyme Cap8C | −2.91 | |
| SAOUHSC_00117 | Capsular polysaccharide biosynthesis protein Cap5D | −2.4 | |
| SAOUHSC_00119 | Capsular polysaccharide synthesis enzyme Cap8F | −2.34 | |
| SAOUHSC_00122 | Capsular polysaccharide biosynthesis protein Cap5I | −2.1 | |
| SAOUHSC_00124 | Capsular polysaccharide biosynthesis protein Cap5K | −2.18 | |
| SAOUHSC_00126 | Capsular polysaccharide biosynthesis protein Cap8M | −2.02 | |
| SAOUHSC_00127 | Cap5N protein/UDP-glucose 4-epimerase, putative | −2.14 | |
| SAOUHSC_00222 | TagB protein, putative | 2.24 | |
| SAOUHSC_00295 | N-acetylneuraminate lyase | −2.02 | |
| SAOUHSC_00469 | Regulatory protein SpoVG | −2.51 | |
| SAOUHSC_00545 | sdrD protein, putative | −3.68 | |
| SAOUHSC_00640 | Teichoic acid biosynthesis protein | −2.08 | |
| SAOUHSC_00812 | Clumping factor, ClfA | −4.72 | |
| SAOUHSC_00918 | | Truncated MHC class II analog protein | 2.15 |
| SAOUHSC_00953 | | Diacylglycerol glucosyltransferase | −2.21 |
| SAOUHSC_00974 | | Glycosyl transferase, group 1 | 4.24 |
| SAOUHSC_01106 | Glutamate racemase, MurI | −2.12 | |
| SAOUHSC_01145 | Penicillin-binding protein 1 | −2.05 | |
| SAOUHSC_01147 | UDP-N-acetylmuramoylalanine--D-glutamate ligase, MurD | −2.58 | |
| SAOUHSC_01148 | Cell division protein, putative | −2.38 | |
| SAOUHSC_01346 | | Glycine betaine transporter, putative | 4.62 |
| SAOUHSC_01400 | | Alanine racemase, putative | −2.81 |
| SAOUHSC_02317 | UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate--D-alanyl-D-alanyl ligase | −2.3 | |
| SAOUHSC_02318 | D-alanyl-alanine synthetase A | −2.34 | |
| SAOUHSC_02399 | Glucosamine--fructose-6-phosphate aminotransferase | −2.05 | |
| SAOUHSC_02444 | | Osmoprotectant transporter, BCCT family, opuD-like protein | −2.86 |
| SAOUHSC_02998 | Capsular polysaccharide biosynthesis protein, Cap5C | 2.04 | |
a “-” indicates down-regulated in the airSR mutant.
Figure 1The Triton X-100 induced autolysis. The wild-type, the airSR mutant, and the complementary strain in Tris–HCl buffer containing 0.05% Trition X-100 at 37°C. (**indicates P < 0.01).
Figure 2Vancomycin susceptibility assay. (a) Colony counts (CFU/ml) of WT, the airSR mutant, and the airSR complementary strains on MH agar plates containing vancomycin (0.6 μg/ml). The colonies were counted after incubation at 37°C for 24 hours. (b) The growth of the wild-type, the airSR mutant, and the airSR complementary strains in MH broth at 37°C. Vancomycin concentrations of 0 or 1.0 μg/ml. (**indicates P < 0.01).
Figure 3Transcriptional level of several cell wall-related genes. Comparison of the relative transcription levels of several cell wall biosynthesis- and hydrolysis-related genes in the wild-type, the airSR mutant, and the airSR complementary strains. (a), (b), and (c) transcriptional levels under aerobic conditions in different time courses; (d) transcriptional levels under anaerobic conditions. (*indicates P < 0.05; **indicates P < 0.01).
Figure 4Electrophoretic mobility shift assay for AirR. The first lane was the free DNA probe (2 nM); the second to fourth lanes were the DNA probe with increasing amounts of AirR (0.3, 0.6, and 1.2 μM); the fifth lane was the same as the fourth lane but with the addition of a 50-fold excess of unlabeled probes as specific competitors (SCs). The sixth lane was as the same as the fourth lane but with the addition of a 50-fold excess of unlabeled pta ORF region fragments as non-specific competitor. (NC). (a) EMSA with cap promoter; (b) ddl promoter; (c) pbp1 promoter; (d) lytM promoter.